Ken Griffin En V Veno Medical Corp Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.24 - $6.19 $9,396 - $17,951	-2,900 Reduced 7.75%	34,500 $115,000
Q2 2024 Aug 14, 2024	SELL	$4.62 - $5.5 $54,978 - $65,450	-11,900 Reduced 24.14%	37,400 $196,000
Q1 2024 May 15, 2024	BUY	$3.94 - $6.65 $107,562 - $181,545	27,300 Added 124.09%	49,300 $268,000
Q4 2023 Feb 14, 2024	BUY	$3.46 - $5.73 $76,120 - $126,060	22,000 New	22,000 $113,000
Q2 2023 Aug 14, 2023	BUY	$2.6 - $5.19 $13,780 - $27,507	5,300 New	5,300 $16,000
Q4 2022 Feb 14, 2023	SELL	$4.54 - $6.6 $194,766 - $283,140	-42,900 Reduced 86.49%	6,700 $34,000
Q3 2022 Nov 14, 2022	BUY	$0.1 - $7.82 $2,700 - $211,140	27,000 Added 119.47%	49,600 $311,000

5.61M

89.3K

5.2K

Ticker NVNO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 9,469,850
Market Cap $32.3M
Description
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.